论文部分内容阅读
近40年来,左旋多巴(L—dopa)在国际上已被公认为是治疗帕金森氏病(PD)最有效的药物。但长期应用,不仅疗效逐渐降低,且会出现一系列运动波动的表现及药物不良反应。多巴胺D_2受体激动剂溴隐亭作为PD治疗中的辅助用药,于70年代广泛用于临床。80年代,新一代多巴胺受体激动剂协良行(Celance,Pergolide,甲磺酸培多利特)问世,并应用于临床。协良行除了具有强有力的D_2受体激动作用外,同时还具有D_1受体激动作用。国外诸多的临床应用经验表明,协良行无论单独应
For nearly 40 years, L-dopa has been recognized internationally as the most effective drug for the treatment of Parkinson’s disease (PD). However, long-term use, not only the efficacy gradually decreased, and there will be a series of performance fluctuations and adverse drug reactions. Dopamine D 2 receptor agonist bromocriptine is widely used clinically as an adjuvant in the treatment of PD in the 1970s. In the 1980s, a new generation of dopamine receptor agonist Xie Liang line (Celance, Pergolide, pemetrexed) come out and applied to the clinic. In addition to having a potent D_2 receptor agonist, Coleraine also has D_1 receptor agonism. Many foreign clinical experience shows that Xie Liang line should be alone